Anti-covid, antiviral ensitrelvir
TL:DR – An antiviral drug called ensitrelvir could cut the time a person tests positive when they have COVID-19 by about a day. There is a controversial suggestion that it might also reduce the risk of developing long-covid.
An antiviral drug developed by Shionogi in partnership with Hokkaido University is an orally active 3C-like protease inhibitor, which can shorten the time between first testing positive after infection with SARS-CoV-2 and getting a negative test. Early signs are that it may well reduce the risk of developing long-covid, although that data is yet to be peer reviewed. There are some scientists sce...
Source: David Bradley Sciencebase - Songs, Snaps, Science - March 10, 2023 Category: Science Authors: David Bradley Tags: COVID-19 Pharma Source Type: blogs
TWiV 945: Clinical update with Dr. Daniel Griffin
In his weekly clinical update Dr. Griffin discusses a healthcare-associated infection with Monkeypox virus, air and surface sampling for monkeypox virus in a UK hospital, misrepresentation and nonadherence regarding COVID19 public health measures, tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine, clinical, virologic, and immunologic evaluation of symptomatic rebound following Nirmatrelvir/Ritonavir treatment, early outpatient treatment with Eemdesivir in patients at high risk for severe COVID-19, Molnupiravir plus usual care versus usual care alone as early treatme...
Source: virology blog - October 15, 2022 Category: Virology Authors: Vincent Racaniello Tags: This Week in Virology antiviral coronavirus COVID-19 delta inflammation influenza Long Covid marburg virus monkeypox monoclonal antibody Omicron pandemic poliovirus SARS-CoV-2 vaccine vaccine booster variant of concern Source Type: blogs
Commentators and Journalists Weigh In On Digital Health And Related Privacy, Safety, Social Media And Security Matters. Lots Of Interesting Perspectives - July 26, 2022.
-----This weekly blog is to explore the news around the larger issues around Digital Health, data security, data privacy, AI / ML. technology, social media and related matters.I will also try to highlightADHA Propagandawhen I come upon it.Just so we keep count, the latest Notes from the ADHA Board were dated 6 December, 2018 and we have seen none since! It ’s pretty sad!Note: Appearance here is not to suggest I see any credibility or value in what follows. I will leave it to the reader to decide what is worthwhile and what is not! The point is to let people know what is being said / published that I have come upon.-----h...
Source: Australian Health Information Technology - July 26, 2022 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs
Before taking Paxlovid, consider these drug interactions
FDA and Health Canada recently approved Paxlovid as an oral treatment option for mild-to-moderate COVID-19 who are at high risk of progression to severe COVID-19. It is a combination drug containing nirmatrelvir/ritonavir. Nirmatrelvir works by binding to SARS-CoV-2 3CL protease to ultimately stop viral replication. Ritonavir does not have any antiviral activity against COVID-19 butRead more …Before taking Paxlovid, consider these drug interactions originally appeared inKevinMD.com. (Source: Kevin, M.D. - Medical Weblog)
Source: Kevin, M.D. - Medical Weblog - April 7, 2022 Category: General Medicine Authors: < span itemprop="author" > < a href="https://www.kevinmd.com/post-author/param-patel" rel="tag" > Param Patel, PharmD < /a > < /span > Tags: Meds COVID Infectious Disease Medications Source Type: blogs
Drugs for COVID-19: A Publishing Epidemic
As of April 9, PubMed listed 2,868 scientific publications which incorporate the word “COVID”. 323 of these (11.3%) were related to drugs under study for treatment of the disease. No fewer than thirty-one such drugs had been proposed since this pandemic first appeared on the planet four months earlier.
Graph 1 depicts the cumulative numbers of COVID-19 infection (per 100,000 global population) and introductions of relevant drugs into the Literature during February 14 to April 3. Note that both increased by a factor of approximately 16-fold during this period.
In a...
Source: GIDEON blog - April 12, 2020 Category: Databases & Libraries Authors: Uri Blackman Tags: Epidemiology Graphs Source Type: blogs
Azithromycin and COVID-19
ConclusionA small, preliminary COVID-19 clinical study reported complete clearance of virus after combined administration of azithromycin and hydroxychloroquine as measured by realtime PCR of nasopharyngeal swabs. No study of azithromycin alone was conducted. Despite azithromycin's reputation as an antibacterial agent, scattered reports of in vivo and in vitro antiviral activity for this drug have been reported. (Source: Depth-First)
Source: Depth-First - March 24, 2020 Category: Chemistry Authors: Richard L. Apodaca Source Type: blogs
Technology and Cooperation Help Fight the Pandemic
Chelsea FollettThe pandemic caused by the new coronavirus (COVID-19) from Wuhan, China, is now a serious and global problem. And that problem has been made even worse by a culture of constant alarmism making it hard to distinguish real threats from exaggerated claims, as the well ‐known science writer Matt Ridley has pointed out. But even when faced with the genuine threat of a pandemic, there are reasons to take heart and think that humanity will rise to the challenges ahead.First, humanity has never been better prepared technologically to deal with a pandemic. We are fortunate to live in an age o...
Source: Cato-at-liberty - March 13, 2020 Category: American Health Authors: Chelsea Follett Source Type: blogs
Tropical Travel Trouble 009 Humongous HIV Extravaganza
LITFL • Life in the Fast Lane Medical Blog LITFL • Life in the Fast Lane Medical Blog - Emergency medicine and critical care medical education blog
aka Tropical Travel Trouble 009
The diagnosis of HIV is no longer fatal and the term AIDS is becoming less frequent. In many countries, people with HIV are living longer than those with diabetes. This post will hopefully teach the basics of a complex disease and demystify some of the potential diseases you need to consider in those who are severely immunosuppressed. While trying to be comprehensive this post can not be exhaustive (as you can imagine any patient with a low ...
Source: Life in the Fast Lane - July 7, 2018 Category: Emergency Medicine Authors: Amanda McConnell Tags: Clinical Cases Tropical Medicine AIDS art cryptococcoma cryptococcus HIV HIV1 HIV2 PEP PrEP TB toxoplasma tuberculoma Source Type: blogs
Pill relief
I’m awaiting delivery of my next two weeks’ worth of medications with a major change in the blister packs. Gone will be Norvir, Prezista, Truvada and Nevirapine, all taken twice a day, and they’re being replaced with ONE pill, Genvoya, ONCE a day containing 4 new-to-me drugs in combination. What a relief, other pills continuing … Continue reading Pill relief (Source: My journey with AIDS)
Source: My journey with AIDS - December 13, 2017 Category: Infectious Diseases Authors: Kenn Tags: AIDS and HIV autobiography health-care medical update Source Type: blogs
A Year in Review: FDA 2015 New Drug Approvals
The approval of first-of-a-kind drugs rose last year to forty-one, resulting in the highest level of newly approved U.S. drugs in nineteen years. The total number of new drugs approved last year was even higher at sixty-nine. The rising figures reflect an industry-wide desire to research and develop drugs for rare and hard-to-treat diseases.
The newly approved drugs serve to advance medical care and the health of patients suffering from many ailments, including various forms of cancer, heart failure, and cystic fibrosis. Additionally, more than 40% of the new therapies were approved for treatment of rare or "orphan" dise...
Source: Policy and Medicine - January 13, 2016 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
As the Hepatitis C Marketing Frenzy Continues, a Reminder Not to Ignore the Evidence
The Hepatitis C Spin Cycle Continues Since our last post in July, 2014, about sofosbuvir (Sovaldi, Gilead), the $1000 pill proclaimed to be a wonder drug for the treatment of hepatitis C, the marketing juggernaut for new antiviral drugs for this condition continues to roll along.For example, I just got a notice to look at a Gilead website which proclaims HCV can be curedIn October, Gilead got permission so sell Harvoni, a new combination drug that includes sofosbuvir and ledipasvir, hailed as a once daily pill that can cure hepatitis C, for a mere $94,500 for a typical treatment course. (See this article in the Wall ...
Source: Health Care Renewal - January 5, 2015 Category: Health Management Tags: AbbeVie clinical trials evidence-based medicine Gilead marketing Sovaldi Source Type: blogs
AIDS Group Sues Abbott And AbbVie Over 340B Drug Discounts
Once again, the AIDS Healthcare Foundation has filed a lawsuit against a drugmaker for allegedly failing to offer required discounts on prescription medicines as part of the 340B Drug Pricing Program. The latest complaint accuses Abbott Laboratories and its AbbVie spin off of overcharging by more than $2 million for HIV drugs between 2005 and 2013 (here is the lawsuit).
This is the second time in recent weeks that AHF, which is an outspoken advocate for expanding services to patients, has filed such a lawsuit against a drugmaker. In October, the medical care provider made nearly identical charges against Johnson & John...
Source: Pharmalot - December 2, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
NIH Rejects Petition About AbbVie Pricing For Norvir AIDS Drug
The US National Institutes of Health has rejected a so-called march-in petition that was sought by several non-profit groups that hoped to make and sell the Norvir HIV medication sold by AbbVie (ABBV). They sought to do so because the drug was created with federal funds and is currently much more expensive in the US than in other countries with comparable incomes (here is the petition).
Norvir is commonly used in HIV drug cocktails, including the Kaletra AIDS pill. Abbott Laboratories, which last year spun off AbbVie, battled patient advocates, consumers and even a rival drugmaker after raising the price by some 400 percen...
Source: Pharmalot - November 7, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
Top stories in health and medicine, October 21, 2013
From MedPage Today:
HIV Dual Therapy Matches Standard Triple Cocktail.A two-drug regimen (lopinavir/ritonavir plus lamivudine) for HIV did as well in controlling the virus as a standard triple-drug cocktail.
Cognitive Therapy Eases Unfounded Health Fears. Patients who worried excessively about their health showed reduced anxiety after cognitive behavioral therapy compared with simple reassurance in a randomized trial.
Formula as Good as Breastmilk for Iodine Levels. Newborns have sufficient iodine levels whether they’re breastfed or formula-fed.
CT, MRI Overused for Headache, Study Finds. Despite current guidelines...
Source: Kevin, M.D. - Medical Weblog - October 21, 2013 Category: Family Physicians Tags: News Infectious disease Neurology Source Type: blogs
